AUTHOR=Torres-Peña Jose D. , Martín-Piedra Laura , Fuentes-Jiménez Francisco 

TITLE=Statins in Non-alcoholic Steatohepatitis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 8 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.777131

DOI=10.3389/fcvm.2021.777131

ISSN=2297-055X

ABSTRACT=Non-alcoholic fatty liver disease (NAFLD) is the first cause of chronic liver disease worldwide. The spectrum is broad from hepatocellular carcinoma, cirrhosis, fibrosis,  fatty liver, non-alcoholic steatohepatitis (NASH). NASH is a condition associated with the metabolic syndrome, overweight, obesity, dyslipidemia and type 2 diabetes mellitus. It is a dynamic condition that can regress to isolated steatosis or progress to fibrosis and cirrhosis. Statins  exert anti-inflammatory, proapoptotic, and antifibrotic effects. It´s has been proposed that this drugs could have a relevant role in NASH. In this review we provide an overview of current evidence, from mechanisms of statins involved in the modulation of NASH to human trials about the use of statins to treat  or attenuate NASH.